Plain language summary of the TOPAZ-1 study: Durvalumab and chemotherapy for advanced biliary tract cancer

Do-Youn Oh
Benjamin Tan
et al.

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

Part of the Medicine and Health Sciences Commons

Please let us know how this document benefits you.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer

Do-Youn Oh¹, Aiwu Ruth He², Shukui Qin³, Li-Tzong Chen⁴, Takuji Okusaka⁵, Arndt Vogel⁶, Jin Won Kim⁷, Thathnan Sukombooncharoena⁵, Myung Ah Lee⁵, Masayuki Kitano¹⁰, Howard Burris³¹, Mohamed Bouattour²¹, Suebpong Tanasanvimon¹³, Mairéad G. McNamara¹⁴, Renata Zaucha¹⁷, Antonio Avallone¹⁶, Benjamin Tan¹⁷, Juan Cundom¹⁸, Choong-kun Lee¹⁹, Hidenori Takahashi²⁰, Masafumi Ikeda²¹, Jen-Shi Chen²², Julie Wang²³, Mallory Makowsky²³, Nana Rokutanda²³, Magdalena Żotkiewicz²⁴, John F. Kurland²³, Gordon Cohen²³, Juan W. Valle¹⁴

First draft submitted: 25 May 2023; Accepted for publication: 11 August 2023; Published online: 25 September 2023

Summary

What is this summary about?
This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC). Advanced BTC is usually diagnosed at late stages of disease, when it cannot be cured by surgery. This study included participants with advanced BTC who had not received previous treatment, or had their cancer come back at least 6 months after receiving treatment or surgery that aimed to cure their disease. Participants received treatment with durvalumab and chemotherapy or placebo and chemotherapy. The aim of this study was to find out if treatment with durvalumab and chemotherapy could increase the length of time that participants with advanced BTC lived, compared with placebo and chemotherapy.

What were the results of the study?
Participants who took durvalumab and chemotherapy had a 20% lower chance of experiencing death at any point in the study compared with participants who received placebo and chemotherapy. The side effects experienced by participants were similar across treatment groups, and less than 12% of participants in either treatment group had to stop treatment due to treatment-related side effects.

What do the results of the study mean?
Overall, these results support durvalumab and chemotherapy as a new treatment option for people with advanced BTCs. Based on the results of this study, durvalumab is now approved for the treatment of adults with advanced BTCs in combination with chemotherapy by government organizations in Europe, the United States and several other countries.

How to say (double click sound icon to play sound)...
• Durvalumab: dur-VAL-yoo-mab
• Gemcitabine: jem-SY-tuh-been
• Cisplatin: sis-PLA-tin

Phase III study: A study that tests the safety, and how well a new treatment works, compared with a standard treatment.

Immunotherapy: Treatment that targets the immune system to help the body fight cancer.

Chemotherapy: A type of cancer treatment that uses drugs to kill cancer cells.

Placebo: An inactive substance that looks the same and is given in the same way as the active treatment being tested.

Treatment-related side effects: An unintended problem that is related to treatment with a drug or other therapy.

Where can I find the original article on which this summary is based?
The original article discussed in this summary, titled “Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer”, was published in the New England Journal of Medicine Evidence in 2022. This article is available for free at: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200015.
Who sponsored this study and summary?

The pharmaceutical company AstraZeneca (the manufacturer of durvalumab) funded and was responsible for conducting this study. AstraZeneca also funded this plain language summary.

Who should read this article?

This plain language summary may be helpful for people with BTC and their caregivers, patient advocates, and healthcare professionals. This summary may also be helpful to those who are interested in learning about new treatment advances for BTCs.

What are biliary tract cancers (BTCs) and what are the treatment options?

- The biliary tract is part of the digestive system and includes the gallbladder and bile ducts.
- The gallbladder stores bile. The bile ducts (including the left and right hepatic ducts, cystic duct, common hepatic duct, and common bile duct) carry bile from the liver and gallbladder to the small intestine (duodenum).
- BTCs are a group of cancers that include those developing in the gallbladder (gallbladder cancer), the bile ducts in the liver (intrahepatic cholangiocarcinoma), or the bile ducts not in the liver (extrahepatic cholangiocarcinoma).
- Early stages of BTCs can be treated with surgery but many people are diagnosed at late stages of disease, called advanced BTC, which cannot be cured by surgery.
- Historically, the standard of care for people with advanced BTCs has consisted of the combination of two chemotherapy drugs, gemcitabine and cisplatin. However, only around 50% of people survive longer than 1 year after treatment with chemotherapy.
- New treatment options that could benefit people with advanced BTCs are needed. Immunotherapy is a new type of cancer treatment to be tested in people living with advanced BTC. Immunotherapy helps the body’s own immune cells to recognize and kill cancer cells.
What is durvalumab?

- The medication being assessed in this study is a type of immunotherapy called durvalumab. Participants received durvalumab treatment directly into their vein at a dose of 1500 mg once every 3 weeks in combination with chemotherapy, and then durvalumab alone once every 4 weeks.
- Programmed cell death-1 (PD-1) is a protein found on the surface of T cells (immune cells) that interacts with programmed cell death ligand-1 (PD-L1), another protein found on cancer cells or immune cells. This interaction between PD-1 and PD-L1 proteins reduces the activity of T cells and can prevent the immune system from attacking cancer cells.
- Durvalumab is a drug that blocks the interaction of PD-1 and PD-L1 proteins by attaching to PD-L1, leading to activation of T cells and the immune system. Activation of the immune system by durvalumab may result in the death of cancer cells.
- At the time of this study, durvalumab was approved in many countries, including the United States (Food and Drug Administration), European Union (European Commission), and Japan (Ministry of Health, Labour, and Welfare) for the treatment of non-small cell and small cell lung cancer. It was also under investigation for the treatment of several other cancer types, including liver, bladder, gastric, and esophageal cancers.
- Previous research has suggested that durvalumab may work for the treatment of BTCs when it is given in combination with chemotherapy.

Where was the TOPAZ-1 study carried out?

TOPAZ-1 is a Phase III study that included participants with advanced BTCs from all over the world.
Who was eligible to participate in the study?

- Adults aged 18 years or more with BTC, including those with cholangiocarcinoma (cancer of the bile ducts) or gallbladder cancer not suitable for surgery

- Adults with BTC were included if they had not received previous treatment for advanced BTC or if their disease had come back at least 6 months after surgery was performed to cure their disease

- Adults with BTC did not need to have any specific gene mutation to participate in the study

- Adults with BTC had to have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 to be included in the study

  **ECOG performance score is a measurement of how the disease impacts a person’s daily living ability. A score of 0 means that the person is fully active and able to carry out the same activities as before their disease, and a score of 1 means that the person is restricted in physically strenuous activity but able to carry out light work.**

- Adults did not participate in the study if they had cancer of the ampulla of Vater, the junction where the common bile duct meets the pancreatic duct

- Adults with BTC who had active, or a history of, illnesses or conditions where the immune system is already over activated, or a known allergy to any of the treatments given in the study, were not able to participate in the study
What treatment did participants receive?

**685 participants** were included in the study and were allocated to groups at random to receive either durvalumab and chemotherapy (341 participants) or placebo and chemotherapy (344 participants).

In the study, participants were given treatment with durvalumab and chemotherapy or placebo and chemotherapy for up to eight 21-day cycles, followed by treatment with durvalumab or placebo once every 4 weeks until they had to stop, as shown in the diagram below.

**A placebo does not contain any medicine, but it looks the same, and is given in the same way, as the treatment being tested (durvalumab).**

Participants received treatment directly into a vein or veins.

In some cases, participants could stay on treatment even if their cancer grew, spread, or got worse, if their doctors believed they could still benefit from the treatment.

In the study, neither the participants nor their doctors knew if the participant received durvalumab or placebo with chemotherapy. This was done to make sure that any differences measured between the two groups of participants were caused by the treatment only.
The aim of this study was to find out if treatment with durvalumab and chemotherapy could increase the length of time that participants lived, compared with placebo and chemotherapy.

Other outcomes measured in the study included:

- The length of time to when a participant’s cancer grew, spread, or got worse.
- The percentage of participants whose tumor responded to treatment. Response was defined when a participant’s tumor shrank by at least 30% or disappeared after treatment.
- The length of time that a participant’s tumor continued to respond to treatment. Response was defined when a participant’s tumor shrank by at least 30% or disappeared after treatment.
- The length of time that participants with PD-L1 high tumors (defined as 1% or more of cancer and/or immune cells with PD-L1 expression) were alive after treatment compared with those with PD-L1 low tumors (defined as less than 1% of cancer and/or immune cells with PD-L1 expression).
- The impact of the treatment or disease on a participant’s quality of life, which was reported directly by the participant. The quality of life results will be reported elsewhere.
- The side effects of the treatments.
- The results presented in this report are from a planned early analysis of these measures in the TOPAZ-1 study. This analysis was performed using data collected on 11 August 2021.

PD-L1 expression was assessed by looking at tumor samples under the microscope in a laboratory. In some cancer types, durvalumab has been shown to work better for people who have PD-L1 high tumors, as durvalumab works by attaching to this receptor as described above.
Who were the participants in the study?

<table>
<thead>
<tr>
<th></th>
<th>Durvalumab + chemotherapy (341 participants)</th>
<th>Placebo + chemotherapy (344 participants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, %</td>
<td>50.4</td>
<td>48.8</td>
</tr>
<tr>
<td>Median age (range), years</td>
<td>64 (20–84)</td>
<td>64 (31–85)</td>
</tr>
<tr>
<td>Region, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asia</td>
<td>52.2</td>
<td>57.0</td>
</tr>
<tr>
<td>Rest of the world</td>
<td>47.8</td>
<td>43.0</td>
</tr>
<tr>
<td>Race, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>54.3</td>
<td>58.4</td>
</tr>
<tr>
<td>White</td>
<td>38.4</td>
<td>36.0</td>
</tr>
<tr>
<td>Black or African American</td>
<td>2.3</td>
<td>1.7</td>
</tr>
<tr>
<td>American Indian or Alaska Native</td>
<td>0.0</td>
<td>0.3</td>
</tr>
<tr>
<td>Other</td>
<td>5.0</td>
<td>3.5</td>
</tr>
<tr>
<td>ECOG PS 0, %</td>
<td>50.7</td>
<td>47.4</td>
</tr>
<tr>
<td>Primary tumor type, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intrahepatic cholangiocarcinoma</td>
<td>55.7</td>
<td>56.1</td>
</tr>
<tr>
<td>Extrahepatic cholangiocarcinoma</td>
<td>19.4</td>
<td>18.9</td>
</tr>
<tr>
<td>Gallbladder cancer</td>
<td>24.9</td>
<td>25.0</td>
</tr>
<tr>
<td>Disease status, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not eligible for surgery</td>
<td>80.4</td>
<td>81.1</td>
</tr>
<tr>
<td>Returned after surgery</td>
<td>19.6</td>
<td>18.6</td>
</tr>
<tr>
<td>PD-L1 expression, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>57.8</td>
<td>59.6</td>
</tr>
<tr>
<td>Low</td>
<td>30.2</td>
<td>29.9</td>
</tr>
<tr>
<td>Missing (absent)</td>
<td>12.0</td>
<td>10.5</td>
</tr>
</tbody>
</table>

- Participant characteristics and their cancer were similar between the two treatment groups.
- By the end of the study, the most common reason for participants stopping treatment was that their cancer grew.
- Fewer patients stopped treatment because of cancer growth in the durvalumab and chemotherapy group (55.7%) than in the placebo and chemotherapy group (69.2%).
- Other reasons for participants stopping treatment included that they experienced side effects that caused them to stop treatment (5.9% with durvalumab and chemotherapy and 5.2% with placebo and chemotherapy), they decided to leave the study (3.8% with durvalumab and chemotherapy and 4.7% with placebo and chemotherapy), and they improved or recovered from their disease (0.3% with durvalumab and chemotherapy and 0.3% with placebo and chemotherapy).
What did the results of the study show?

How well did the addition of durvalumab to chemotherapy help participants with BTC live longer?

- Participants who received durvalumab and chemotherapy were 20% less likely to die (called reduced risk of death) compared with those who received placebo and chemotherapy.
- Half of the participants still participating in the trial were alive 12.8 months after starting durvalumab and chemotherapy treatment, and half of the participants still participating in the trial were alive 11.5 months after starting placebo and chemotherapy treatment.
- Among those still participating in the trial, more participants who received durvalumab and chemotherapy were alive at 12, 18, and 24 months after starting treatment than participants who received placebo and chemotherapy.

Percentage of participants still participating in the trial who were alive at specific time points after starting treatment

<table>
<thead>
<tr>
<th>Time Point</th>
<th>Durvalumab + chemotherapy (341 participants)</th>
<th>Placebo + chemotherapy (344 participants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 months</td>
<td>54.1%</td>
<td>48.0%</td>
</tr>
<tr>
<td>18 months</td>
<td>35.1%</td>
<td>25.6%</td>
</tr>
<tr>
<td>24 months</td>
<td>24.9%</td>
<td>10.4%</td>
</tr>
</tbody>
</table>

Participants who received durvalumab and chemotherapy tended to live longer than those who received placebo and chemotherapy, regardless of where they lived in the world, the location of their cancer, and whether there was PD-L1 in their tumor.

- Participants who received durvalumab and chemotherapy were 25% less likely to experience their cancer growing, spreading, or getting worse (called disease progression) than those who received placebo and chemotherapy.
- Of those still participating in the trial, the length of time that half the participants were alive without their cancer growing, spreading, or getting worse (called disease progression-free survival) was 7.2 months with durvalumab and chemotherapy and 5.7 months with placebo and chemotherapy.

Statistical tests (mathematical tests used to confirm a significant difference) showed that both survival and survival without cancer growth, spread or worsening were longer in the durvalumab and chemotherapy group compared with the placebo and chemotherapy group.
Results from TOPAZ-1: durvalumab and chemotherapy in advanced BTC  
Plain Language Summary of Publication

- The length of time before half the participants had their cancer shrink or disappear was 6.4 months with durvalumab and chemotherapy and 6.2 months with placebo and chemotherapy. In total, 26.1% of participants in the durvalumab and chemotherapy group still had their cancer shrink or disappear 12 months or more after starting treatment, compared with 15.0% in the placebo and chemotherapy group.

- Participants who received durvalumab and chemotherapy had a shorter time to their cancer shrinking or disappearing than participants who received placebo and chemotherapy. The time point at which half the participants had their cancer shrink or disappear was 1.6 months with durvalumab and chemotherapy compared to 2.7 months with placebo and chemotherapy.

How safe was durvalumab and chemotherapy treatment?

A similar proportion of participants in each treatment group experienced severe side effects considered to be related to the treatment.

**Percentage of patients who had severe side effects related to the treatment**

- 62.7% of the 338 participants who received durvalumab + chemotherapy
- 64.9% of the 342 participants who received placebo + chemotherapy

Severe side effects are medically significant (Grade 3) or potentially life-threatening (Grade 4) side effects, as described by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

**Percentage of patients who had a side effect related to the treatment that led them to stop treatment**

- 8.9% of the 338 participants who received durvalumab + chemotherapy
- 11.4% of the 342 participants who received placebo + chemotherapy
The number of deaths due to side effects caused by the treatment was low in each group: 2 (0.6%) deaths in the durvalumab and chemotherapy group and 1 (0.3%) death in the placebo and chemotherapy group.

**Most common side effects in participants who received treatment**

<table>
<thead>
<tr>
<th>Side Effect</th>
<th>Placebo + chemotherapy (342 participants)</th>
<th>Durvalumab + chemotherapy (338 participants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>28.9%</td>
<td>32.0%</td>
</tr>
<tr>
<td>Constipation</td>
<td>26.3%</td>
<td>26.9%</td>
</tr>
<tr>
<td>Levels of neutrophils decreased during the study</td>
<td>26.9%</td>
<td>26.9%</td>
</tr>
<tr>
<td>Low levels of red blood cells (low blood oxygen</td>
<td>48.2%</td>
<td>44.7%</td>
</tr>
<tr>
<td>levels)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>44.7%</td>
<td>48.2%</td>
</tr>
</tbody>
</table>

Percentage of participants who experienced the side effect

- **Durvalumab + chemotherapy (338 participants)**
- **Placebo + chemotherapy (342 participants)**

*As durvalumab is a type of immunotherapy, it can cause the immune system to become overactive, causing side effects.*

- As expected with immunotherapies, the proportion of participants who experienced a side effect related to the immune system was higher in the durvalumab and chemotherapy group (12.7%) than in the placebo and chemotherapy group (4.7%)
- The proportion of participants who experienced a severe or medically significant (Grade 3) or potentially life-threatening (Grade 4) side effect related to the immune system was 2.4% with durvalumab and chemotherapy and 1.5% with placebo and chemotherapy
This study showed that participants with advanced BTC who received durvalumab and chemotherapy lived significantly longer than participants who received placebo and chemotherapy.

The addition of durvalumab did not make the side effects from chemotherapy worse, and participants experienced side effects that are common with immunotherapy and chemotherapy, most of which were manageable.

The results of this large, global, Phase III study support that durvalumab and chemotherapy are a new initial treatment option for people with advanced BTCs.

Based on the results of this study, durvalumab is now approved for the treatment of adults with advanced BTCs in combination with chemotherapy.

Where can I find more information?

This is a summary of an article called “Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer” originally published in NEJM Evidence: Oh D-Y et al. NEJM Evid. 1(8), EVIDoa2200015 (2022).

You can read the full article at: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200015.

You can read more about the TOPAZ-1 study on the ClinicalTrials.gov website: https://clinicaltrials.gov/ct2/show/NCT03875235.

People with BTCs should ask their healthcare providers for more information about the benefits and risks of any treatment.
Affiliations
1Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea; 2Division of Hematology and Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA; 3Cancer Center of Nanjing, Jinling Hospital, Nanjing, China; 4Kaohsiung Medical University, Kaohsiung, and National Institute of Cancer Research, Tainan, and National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan; 5Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan; 6Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; 7Division of Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea; 8Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 9Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University, Seoul, South Korea; 10Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan; 11Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA; 12Department of Liver Cancer Unit, AP-HP Hôpital Beaujon, Paris, France; 13Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; 14Division of Cancer Sciences, The University of Manchester/The Christie NHS Foundation Trust, Manchester, UK; 15Department of Oncology and Radiotherapy, Medical University of Gdañsk, Gdañsk, Poland; 16Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy; 17Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; 18Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina; 19Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; 20Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan; 21Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; 22Department of Hematology-Oncology, Linkou Chang-Gung Memorial Hospital and Chang-Gung University, Tao-yuan City, Taiwan; 23AstraZeneca, Gaithersburg, MD, USA; 24AstraZeneca, Warsaw, Poland

Acknowledgments
This study was sponsored by AstraZeneca. We thank the participants in this study and their families, all the investigators and study site personnel, and the members of the independent data monitoring committee. We would like to thank Evelyn Goh Chin Cheng for her review and feedback on the manuscript. Medical writing support, under the guidance of authors, was provided by Laura Park, MSc, CMC Connect, a division of IPG Health Medical Communications, and was funded by AstraZeneca, in accordance with Good Publication Practice (GPP 2022) guidelines.

Financial & competing interests disclosure
Do-Youn Oh reports receiving grant or research support from Array, AstraZeneca, BeiGene, Eli Lilly, Handok, MSD, Novartis, and Servier and consultant fees from ASLAN, AstraZeneca, Basilea, Bayer, BeiGene, Bristol Myers Squibb/Celgene, Genentech/Roche, Halozyme, Merck Serono, Novartis, Taiho, Turning Point, Yuhan, and Zymeworks. Aiwu Ruth He reports receiving grant or research support from Genentech and Merck, consultant fees from AstraZeneca, Bristol Myers Squibb, and Genentech/Roche, and speakers’ bureau from Bristol Myers Squibb and Eisai. Shukui Qin has nothing to disclose. Li-Tsong Chen reports receiving grant or research support from Celgene, Ministry of Health and Welfare (Taiwan), Ministry of Science and Technology (Taiwan), Novartis, OBI, Pfizer, Polaris, Syncore, and TTY and honoraria from Eli Lilly, MSD, Novartis, ONO, PharmaEngine, Syncore, and TTY. Takui Okusaka reports receiving grant or research support from AstraZeneca, Baxter, Bristol Myers Squibb, Chugui, Dainippon Sumitomo Pharma, Eisai, Eli Lilly Japan, Kyowa Hakko Kirin, MSD, Nano Carrier, Novartis, ONO, Pfizer, Syneos Health, and Taiho Pharmaceutical, consultant fees from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Meiji Seika Pharma, Nihon Servier, Nippon Shinyaku, and Taiho Pharmaceutical, honoraria from AstraZeneca, AbbVie, Chugai, Daiichi Sankyo, Eisai, Eli Lilly Japan, Nihon Servier, Novartis, ONO, Taiho Pharma, Takeda Pharma, Teijin Pharma and Yakult, and participation on a data safety monitoring board or advisory board for AstraZeneca, Bayer Yakuhin, Bristol Myers Squibb, Chugai, Daiichi Sanyo, Eisai, Eli Lilly Japan, Incyte Corporation, Mundipharma, Nihon Servier, Novartis, ONO, Pfizer, Shire, Takara Bio, and Takeda Pharmaceutical. Arndt Vogel reports receiving consultant fees and honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, BTG, Eisai, Eli Lilly, GlaxoSmithKline, Imaging Equipment Ltd (AAA), Incyte, Ipsyen, Merck, Novartis, Pierre Fabre, Roche, Sanofi, Servier, Sirtex, and Terumo. Jin Won Kim reports receiving grant or research support from Inno.N and JieI Pharm and consultant fees from AstraZeneca, BeiGene, Beyond Bio, Bristol Myers Squibb/Celgene, Eisai, GC Cell, MSD, ONO, Sanofi-Aventis, Servier, and TCBUsit. Thathan Suksumbooncharoen reports receiving consultant fees from AstraZeneca, Novartis, and Roche/Genentech and honoraria from AstraZeneca, Baxter, Bayer, Bristol Myers Squibb, Eli Lilly, Janssen, MSD, Novartis, Pfizer, and Takeda Pharmaceutical. Myung Ah Lee has nothing to disclose. Masayuki Kitano reports receiving grant or research support from AbbVie and Takeda Pharmaceutical and honoraria from EA Pharma. Howard Burris reports receiving grant or research support from AbbVie, Agios, Arch, ARMO Biosciences, Array BioPharma, Arvinas, AstraZeneca, Bayer, BIND Therapeutics, BioAtla, BioMed Valley, BioTheryx, Boehringer Ingelheim, Bristol Myers Squibb, CALGB, CicloMed, Coordination Pharmaceuticals, CytoMx, eFEFFCTOR Therapeutics, Eli Lilly, EMD Serono, Foundation Medicine, Gossamer Bio, Gilead Sciences, GlaxoSmithKline, Harpoon Therapeutics, Hengrui Therapeutics, Incyte, Infinity Pharmaceuticals, Janssen, Jounce Therapeutics, Kymab, MacroGenics, MedImmune, Merck, Millennium/Takeda Pharmaceuticals, mRNA Therapeutics, Moderna, NGM Biopharmaceuticals, Novartis, Pfizer, Revolution Medicine, Roche/Genentech, Ryvu Therapeutics, Seattle Genetics, Tesaro, TG Therapeutics, Verastem, Vertex Pharmaceuticals, XIbiotech, and Zymeworks, and consultant fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, FORMA Therapeutics, GRAIL, Incyte, Novartis, Pfizer, and Vincere. Mohamed Bouattour reports receiving consultant fees from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsyen, MSD, Roche, and Sirtex Medical. Suebpong Tanasanvimon reports receiving honoraria...
Results from TOPAZ-1: durvalumab and chemotherapy in advanced BTC  Plain Language Summary of Publication

from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, MSD, Novartis, and Roche. Mairéad McNamara reports receiving grant or research support from Ipsen, NuCana, and Servier, consultant fees from Incyte, and honoraria from Advanced Accelerator Applications. Renata Zaucha reports receiving grant or research support from Novartis and honoraria from AstraZeneca, Bristol Myers Squibb, Eisai, Ipsen, and Roche. Antonio Avallone reports receiving grant or research support from Amgen, Bayer, and Bristol Myers Squibb, consultant fees from Amgen, Eisai, and MSD, and honoraria from Amgen, AstraZeneca, MSD, and Servier. Benjamin Tan reports grant or research support (through institution) from Adaptimmune, AstraZeneca, Bristol Myers Squibb, Exelixis, and Zymeworks. Juan Cundom reports receiving consultant fees from Amgen, AstraZeneca, Boehringer Ingelheim, MSD, Pfizer, Roche, and Takeda. Choong-kun Lee has nothing to disclose. Hidenori Takahashi reports receiving grant, research support, or honoraria from AstraZeneca, Daiichi Sankyo, Taiho Pharmaceutical, and Yakult. Masafumi Ikeda reports receiving grant or research support from ASLAN, AstraZeneca, Bayer, Bristol Myers Squibb, Chiome Bioscience, Chugai, Delta-Fly Pharma, EA Pharma, Eisai, Eli Lilly Japan, J-Pharma, Merck, Merus N.V., Nihon Servier, Novartis, ONO, Pfizer, Takeda, and Yakult, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astellas, Bayer, Bristol Myers Squibb, Chugai, Eisai, Eli Lilly Japan, MSD, Nihon Servier, Novartis, Otsuka, Sumitomo Dainippon, Taiho, Takeda, Teijin Pharma, and Yakult, and participation on a data safety monitoring board or advisory board for ASLAN, Bayer, Bristol Myers Squibb, Chugai, Eisai, Eli Lilly Japan, GlaxoSmithKline, Nihon Servier, Novartis, and Takeda. Jen-Shi Chen reports receiving grant or research support from Astellas, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Merck KGaA, MSD Oncology, ONO, Roche, Senhwa Biosciences, Syncore, and TTY Biopharm, and consultant fees from ONO. Julie Wang, Mallory Makowsky, Nana Rokutanda, Magdalena Żotkiewicz, John F. Kurland, and Gordon Cohen are employees and shareholders of AstraZeneca. Juan W. Valle reports receiving grant or research support from NuCana and consultant fees from Agios, Baxter, Genoscience Pharma, Hutchison Medipharma, Imaging Equipment Ltd (AAA), Incyte, Ipsen, Mundipharma EDO, Mylan, NuCana, QED, Servier, Sirtex, and Zymeworks.